Showing Results for
- Academic Journals (13)
Search Results
- 13
Academic Journals
- 13
-
From:PLoS ONE (Vol. 9, Issue 4) Peer-ReviewedObjectives: To evaluate the incidence, type, severity and predictors of antiretroviral and/or anti-tuberculosis drugs induced liver injury (DILI). Methods: A total of 1,060 treatment naive patients were prospectively...
-
From:PLoS ONE (Vol. 8, Issue 7) Peer-ReviewedObjectives We evaluated the importance of ethnicity and pharmacogenetic variations in determining efavirenz pharmacokinetics, auto-induction and immunological outcomes in two African populations. Methods ART...
-
From:PLoS ONE (Vol. 6, Issue 12) Peer-ReviewedBackground Implication of pharmacogenetic variations and efavirenz pharmacokinetics in concomitant efavirenz based antiviral therapy and anti-tubercular drug induced liver injury (DILI) has not been yet studied. We...
-
From:Annals of Thoracic Medicine (Vol. 2, Issue 4) Peer-ReviewedByline: Getachew. Aderaye, Haimanot. G/Egziabher, Abraham. Aseffa, Alemayehu. Worku, Lars. Lindquist Background : Smear-negative tuberculosis occurs more frequently in human immunodeficiency virus (HIV)-infected...
-
From:PLoS ONE (Vol. 10, Issue 5) Peer-ReviewedBackground Given the high death rate the first two months of tuberculosis (TB) therapy in HIV patients, it is critical defining the optimal time to initiate combination antiretroviral therapy (cART). Methods A...
-
From:Pharmacogenomics (Vol. 16, Issue 10) Peer-ReviewedAuthor(s): Abiy Habtewold aff1 aff2 , Eyasu Makonnen aff2 , Wondwossen Amogne aff3 aff4 , Getnet Yimer aff1 aff2 , Getachew Aderaye aff3 , Leif Bertilsson aff1 , Jürgen Burhenne aff5 , Eleni Aklillu [*] aff1 Keywords...
-
From:PLoS ONE (Vol. 3, Issue 3) Peer-ReviewedBackground To assess and compare the prevalence, severity and prognosis of anti-TB drug induced hepatotoxicity (DIH) in HIV positive and HIV negative tuberculosis (TB) patients in Ethiopia. Methodology/Principal...
-
From:JAMA, The Journal of the American Medical Association (Vol. 272, Issue 16) Peer-ReviewedCitation Only
-
From:PLoS ONE (Vol. 11, Issue 6) Peer-ReviewedBackground There are limited data on the performance of the use of fixed-dose combination (FDC) TB drugs when used under programmatic settings in high TB-endemic countries. We evaluated the efficacy and safety of FDC...